The impact of infection on chronic allograft dysfunction and allograft survival after solid organ transplantation

American Journal of Transplantation

Volumn 15, Issue 12, 2015, Pages 3024-3040

  Martin Gandul, C ^a   Mueller, N J ^b   Pascual, M ^a   Manuel, O ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; INFLUENZA VACCINE; OSELTAMIVIR; SIMEPREVIR; SOFOSBUVIR; VALACICLOVIR; ZANAMIVIR; ANTIINFECTIVE AGENT;

ANTIBODY MEDIATED REJECTION; ANTIVIRAL THERAPY; ASPERGILLOSIS; BACTERIAL INFECTION; BACTERIAL RESPIRATORY TRACT INFECTION; BK VIRUS INFECTION; CHRONIC DISEASE; CLINICAL STUDY; COMMUNITY ACQUIRED INFECTION; COMMUNITY ACQUIRED RESPIRATORY VIRUS INFECTION; CYTOMEGALOVIRUS INFECTION; GRAFT DYSFUNCTION; GRAFT RECIPIENT; GRAFT SURVIVAL; HEART TRANSPLANTATION; HEPATITIS C; HERPES VIRUS INFECTION; HETEROLOGOUS IMMUNITY; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; INFECTION PREVENTION; INFLAMMATION; INFLUENZA; INFLUENZA VACCINATION; INTRACELLULAR BACTERIUM; KIDNEY PANCREAS TRANSPLANTATION; KIDNEY TRANSPLANTATION; LIVER GRAFT; MEMORY T LYMPHOCYTE; MYCOSIS; NONHUMAN; ORGAN TRANSPLANTATION; POLYOMAVIRUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; RESPIRATORY VIRUS; REVIEW; SOLID ORGAN TRANSPLANTATION; URINARY TRACT INFECTION; VIRUS INFECTION; ADVERSE EFFECTS; ALLOGRAFT; COMPLICATION; GRAFT REJECTION; INFECTION; PATHOPHYSIOLOGY; PROGNOSIS;

ALLOGRAFTS; ANTI-INFECTIVE AGENTS; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; INFECTION; ORGAN TRANSPLANTATION; PROGNOSIS;

EID: 84948673009     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13486     Document Type: Review

References (210)

1. Kim WR, Smith JM, Skeans MA, et al., OPTN/SRTR 2012 annual data report: Liver. Am J Transplant 2014; 14(Suppl 1): 69-96.
2. Matas AJ, Smith JM, Skeans MA, et al., OPTN/SRTR 2012 annual data report: Kidney. Am J Transplant 2014; 14(Suppl 1): 11-44.
3. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB., Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002; 346: 580-590.
4. Fishman JA,. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357: 2601-2614.
5. Lodhi SA, Lamb KE, Meier-Kriesche HU., Solid organ allograft survival improvement in the United States: The long-term does not mirror the dramatic short-term success. Am J Transplant 2011; 11: 1226-1235.
6. Lamb KE, Lodhi S, Meier-Kriesche HU., Long-term renal allograft survival in the United States: A critical reappraisal. Am J Transplant 2011; 11: 450-462.
7. Land WG., Chronic allograft dysfunction: A model disorder of innate immunity. Biomed J 2013; 36: 209-228.
8. Razonable RR, Paya CV., Infections and allograft rejection-intertwined complications of organ transplantation. Swiss Med Wkly 2005; 135: 571-573.
9. Shoskes DA., Nonimmunologic renal allograft injury and delayed graft function: Clinical strategies for prevention and treatment. Transplant Proc 2000; 32: 766-768.
10. Sato M, Waddell TK, Wagnetz U, et al., Restrictive allograft syndrome (RAS): A novel form of chronic lung allograft dysfunction. J Heart Lung Transplant 2011; 30: 735-742.
11. Verleden SE, Ruttens D, Vandermeulen E, et al., Bronchiolitis obliterans syndrome and restrictive allograft syndrome: Do risk factors differ ? Transplantation 2013; 95: 1167-1172.
12. Lund LH, Edwards LB, Kucheryavaya AY, et al., The registry of the International Society for Heart and Lung Transplantation: Thirty-first official adult heart transplant report-2014; focus theme: Retransplantation. J Heart Lung Transplant 2014; 33: 996-1008.
13. Yusen RD, Edwards LB, Kucheryavaya AY, et al., The registry of the International Society for Heart and Lung Transplantation: Thirty-first adult lung and heart-lung transplant report-2014; focus theme: Retransplantation. J Heart Lung Transplant 2014; 33: 1009-1024.
14. Chapman JR, O'Connell PJ, Nankivell BJ., Chronic renal allograft dysfunction. J Am Soc Nephrol 2005; 16: 3015-3026.
15. Adam R, Karam V, Delvart V, et al., Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol 2012; 57: 675-688.
16. Kumar H, Kawai T, Akira S., Pathogen recognition by the innate immune system. Int Rev Immunol 2011; 30: 16-34.
17. Heeger PS, Greenspan NS, Kuhlenschmidt S, et al., Pretransplant frequency of donor-specific, IFN-gamma-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes. J Immunol 1999; 163: 2267-2275.
18. Adams AB, Williams MA, Jones TR, et al., Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 2003; 111: 1887-1895.
19. Chong AS, Alegre ML., The impact of infection and tissue damage in solid-organ transplantation. Nat Rev Immunol 2012; 12: 459-471.
20. Dickenmann MJ, Cathomas G, Steiger J, Mihatsch MJ, Thiel G, Tamm M., Cytomegalovirus infection and graft rejection in renal transplantation. Transplantation 2001; 71: 764-767.
21. Nett PC, Heisey DM, Fernandez LA, Sollinger HW, Pirsch JD., Association of cytomegalovirus disease and acute rejection with graft loss in kidney transplantation. Transplantation 2004; 78: 1036-1041.
22. Cainelli F, Vento S., Infections and solid organ transplant rejection: A cause-and-effect relationship ? Lancet Infect Dis 2002; 2: 539-549.
23. Craigen JL, Yong KL, Jordan NJ, et al., Human cytomegalovirus infection up-regulates interleukin-8 gene expression and stimulates neutrophil transendothelial migration. Immunology 1997; 92: 138-145.
24. Koskinen PK, Kallio EA, Tikkanen JM, Sihvola RK, Hayry PJ, Lemstrom KB., Cytomegalovirus infection and cardiac allograft vasculopathy. Transpl Infect Dis 1999; 1: 115-126.
25. Helantera I, Egli A, Koskinen P, Lautenschlager I, Hirsch HH., Viral impact on long-term kidney graft function. Infect Dis Clin North Am 2010; 24: 339-371.
26. Botha P, Archer L, Anderson RL, et al., Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome. Transplantation 2008; 85: 771-774.
27. Muller V, Becker G, Delfs M, Albrecht KH, Philipp T, Heemann U., Do urinary tract infections trigger chronic kidney transplant rejection in man ? J Urol 1998; 159: 1826-1829.
28. Tomee JF, Wierenga AT, Hiemstra PS, Kauffman HK., Proteases from Aspergillus fumigatus induce release of proinflammatory cytokines and cell detachment in airway epithelial cell lines. J Infect Dis 1997; 176: 300-303.
29. de Carvalho MA, Freitas FG, Silva Junior HT, Bafi AT, Machado, FR, Pestana, JO., Mortality predictors in renal transplant recipients with severe sepsis and septic shock. PLoS One 2014; 9: e111610.
30. Schaub S, Hirsch HH, Dickenmann M, et al., Reducing immunosuppression preserves allograft function in presumptive and definitive polyomavirus-associated nephropathy. Am J Transplant 2010; 10: 2615-2623.
31. Jacobsen T, Sifontis N., Drug interactions and toxicities associated with the antiviral management of cytomegalovirus infection. Am J Health Syst Pharm 2010; 67: 1417-1425.
32. Bando K, Paradis IL, Similo S, et al., Obliterative bronchiolitis after lung and heart-lung transplantation. An analysis of risk factors and management. J Thorac Cardiovasc Surg 1995; 110: 4-13; discussion 14.
33. Stern M, Hirsch H, Cusini A, et al., Cytomegalovirus serology and replication remain associated with solid organ graft rejection and graft loss in the era of prophylactic treatment. Transplantation 2014; 98: 1013-1018.
34. Desai R, Collett D, Watson CJ, Johnson PJ, Moss P, Neuberger J., Impact of cytomegalovirus on long-term mortality and cancer risk after organ transplantation. Transplantation 2015; 99: 1989-1994.
35. Paraskeva M, Bailey M, Levvey BJ, et al., Cytomegalovirus replication within the lung allograft is associated with bronchiolitis obliterans syndrome. Am J Transplant 2011; 11: 2190-2196.
36. Tong CY, Bakran A, Peiris JS, Muir P, Herrington CS., The association of viral infection and chronic allograft nephropathy with graft dysfunction after renal transplantation. Transplantation 2002; 74: 576-578.
37. Sagedal S, Nordal KP, Hartmann A, et al., The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2002; 2: 850-856.
38. Griffiths PD, Ait-Khaled M, Bearcroft CP, et al., Human herpesviruses 6 and 7 as potential pathogens after liver transplant: Prospective comparison with the effect of cytomegalovirus. J Med Virol 1999; 59: 496-501.
39. Evans PC, Smith S, Hirschfield G, et al., Recipient HLA-DR3, tumour necrosis factor-alpha promoter allele-2 (tumour necrosis factor-2) and cytomegalovirus infection are interrelated risk factors for chronic rejection of liver grafts. J Hepatol 2001; 34: 711-715.
40. Simon CO, Seckert CK, Dreis D, Reddehase MJ, Grzimek NK., Role for tumor necrosis factor alpha in murine cytomegalovirus transcriptional reactivation in latently infected lungs. J Virol 2005; 79: 326-340.
41. Lautenschlager I, Soots A, Krogerus L, et al., Effect of cytomegalovirus on an experimental model of chronic renal allograft rejection under triple-drug treatment in the rat. Transplantation 1997; 64: 391-398.
42. Kloover JS, Soots AP, Krogerus LA, et al., Rat cytomegalovirus infection in kidney allograft recipients is associated with increased expression of intracellular adhesion molecule-1 vascular adhesion molecule-1, and their ligands leukocyte function antigen-1 and very late antigen-4 in the graft. Transplantation 2000; 69: 2641-2647.
43. Helantera I, Loginov R, Koskinen P, Tornroth T, Gronhagen-Riska C, Lautenschlager I., Persistent cytomegalovirus infection is associated with increased expression of TGF-beta1, PDGF-AA and ICAM-1 and arterial intimal thickening in kidney allografts. Nephrol Dial Transplant 2005; 20: 790-796.
44. Dzabic M, Rahbar A, Yaiw KC, et al., Intragraft cytomegalovirus protein expression is associated with reduced renal allograft survival. Clin Infect Dis 2011; 53: 969-976.
45. Evans PC, Soin A, Wreghitt TG, Taylor CJ, Wight DG, Alexander GJ., An association between cytomegalovirus infection and chronic rejection after liver transplantation. Transplantation 2000; 69: 30-35.
46. Smith MA, Sundaresan S, Mohanakumar T, et al., Effect of development of antibodies to HLA and cytomegalovirus mismatch on lung transplantation survival and development of bronchiolitis obliterans syndrome. J Thorac Cardiovasc Surg 1998; 116: 812-820.
47. Opelz G, Dohler B, Ruhenstroth A., Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: A collaborative transplant study report. Am J Transplant 2004; 4: 928-936.
48. Johansson I, Martensson G, Nystrom U, Nasic S, Andersson R., Lower incidence of CMV infection and acute rejections with valganciclovir prophylaxis in lung transplant recipients. BMC Infect Dis 2013; 13: 582.
49. Everett JP, Hershberger RE, Norman DJ, et al., Prolonged cytomegalovirus infection with viremia is associated with development of cardiac allograft vasculopathy. J Heart Lung Transplant 1992; 11: S133 -S137.
50. Delgado JF, Reyne AG, de Dios S, et al., Influence of cytomegalovirus infection in the development of cardiac allograft vasculopathy after heart transplantation. J Heart Lung Transplant 2015; 34: 1112-1119.
51. Thomas LD, Milstone AP, Miller GG, Loyd JE, Stephen Dummer J., Long-term outcomes of cytomegalovirus infection and disease after lung or heart-lung transplantation with a delayed ganciclovir regimen. Clin Transplant 2009; 23: 476-483.
52. Manuel O, Kralidis G, Mueller NJ, et al., Impact of antiviral preventive strategies on the incidence and outcomes of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2013; 13: 2402-2410.
53. Sharples LD, Tamm M, McNeil K, Higenbottam TW, Stewart S, Wallwork J., Development of bronchiolitis obliterans syndrome in recipients of heart-lung transplantation-early risk factors. Transplantation 1996; 61: 560-566.
54. Sharples LD, McNeil K, Stewart S, Wallwork J., Risk factors for bronchiolitis obliterans: A systematic review of recent publications. J Heart Lung Transplant 2002; 21: 271-281.
55. Manuel O, Kumar D, Moussa G, et al., Lack of association between beta-herpesvirus infection and bronchiolitis obliterans syndrome in lung transplant recipients in the era of antiviral prophylaxis. Transplantation 2009; 87: 719-725.
56. Neurohr C, Huppmann P, Leuchte H, et al., Human herpesvirus 6 in bronchalveolar lavage fluid after lung transplantation: A risk factor for bronchiolitis obliterans syndrome ? Am J Transplant 2005; 5: 2982-2991.
57. Verleden SE, Ruttens D, Vandermeulen E, et al., Restrictive chronic lung allograft dysfunction: Where are we now ? J Heart Lung Transplant 2015; 34: 625-630.
58. Lemstrom K, Sihvola R, Bruggeman C, Hayry P, Koskinen P., Cytomegalovirus infection-enhanced cardiac allograft vasculopathy is abolished by DHPG prophylaxis in the rat. Circulation 1997; 95: 2614-2616.
59. Orloff SL, Hwee YK, Kreklywich C, et al., Cytomegalovirus latency promotes cardiac lymphoid neogenesis and accelerated allograft rejection in CMV naive recipients. Am J Transplant 2011; 11: 45-55.
60. Koskinen P, Lemstrom K, Bruggeman C, Lautenschlager I, Hayry P., Acute cytomegalovirus infection induces a subendothelial inflammation (endothelialitis) in the allograft vascular wall. A possible linkage with enhanced allograft arteriosclerosis. Am J Pathol 1994; 144: 41-50.
61. Brunner-La Rocca HP, Schneider J, Kunzli A, Turina M, Kiowski W. Cardiac allograft rejection late after transplantation is a risk factor for graft coronary artery disease. Transplantation 1998; 65: 538-543.
62. Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE., Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989; 261: 3561-3566.
63. Labarrere CA, Lee JB, Nelson DR, Al-Hassani M, Miller SJ, Pitts DE., C-reactive protein, arterial endothelial activation, and development of transplant coronary artery disease: A prospective study. Lancet 2002; 360: 1462-1467.
64. Wahlers T, Fieguth HG, Jurmann M, et al., Graft coronary vasculopathy in cardiac transplantation-evaluation of risk factors by multivariate analysis. Eur J Cardiothorac Surg 1996; 10: 1-5.
65. Arthurs SK, Eid AJ, Pedersen RA, et al., Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 2008; 46: 840-846.
66. Khan H, Mubarak M, Aziz T, et al., Prevalence and risk factors for early chronic allograft nephropathy in a live related renal transplant program. J Nephropathol 2014; 3: 69-79.
67. Courivaud C, Bamoulid J, Chalopin JM, et al., Cytomegalovirus exposure and cardiovascular disease in kidney transplant recipients. J Infect Dis 2013; 207: 1569-1575.
68. Opelz G, Dohler B., Reduced rate of cardiovascular death after cytomegalovirus prophylaxis in renal transplant recipients. Transplantation 2015; 99: 1197-1202.
69. O'Grady JG, Alexander GJ, Sutherland S, et al., Cytomegalovirus infection and donor/recipient HLA antigens: Interdependent co-factors in pathogenesis of vanishing bile-duct syndrome after liver transplantation. Lancet 1988; 2: 302-305.
70. Ludwig J, Wiesner RH, Batts KP, Perkins JD, Krom RA., The acute vanishing bile duct syndrome (acute irreversible rejection) after orthotopic liver transplantation. Hepatology 1987; 7: 476-483.
71. Inomata Y, Tanaka K., Pathogenesis and treatment of bile duct loss after liver transplantation. J Hepatobiliary Pancreat Surg 2001; 8: 316-322.
72. Arnold JC, Portmann BC, O'Grady JG, Naoumov NV, Alexander GJ, Williams R., Cytomegalovirus infection persists in the liver graft in the vanishing bile duct syndrome. Hepatology 1992; 16: 285-292.
73. Lautenschlager I, Hockerstedt K, Jalanko H, et al., Persistent cytomegalovirus in liver allografts with chronic rejection. Hepatology 1997; 25: 190-194.
74. Bosch W, Heckman MG, Diehl NN, Shalev JA, Pungpapong S, Hellinger WC., Association of cytomegalovirus infection and disease with death and graft loss after liver transplant in high-risk recipients. Am J Transplant 2011; 11: 2181-2189.
75. de Otero J, Gavalda J, Murio E, et al., Cytomegalovirus disease as a risk factor for graft loss and death after orthotopic liver transplantation. Clin Infect Dis 1998; 26: 865-870.
76. Lowance D, Neumayer HH, Legendre CM, et al., Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999; 340: 1462-1470.
77. Kalil AC, Freifeld AG, Lyden ER, Stoner JA., Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: An evidence-based reassessment of safety and efficacy. PLoS One 2009; 4: e5512.
78. Owers DS, Webster AC, Strippoli GF, Kable K, Hodson EM., Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2013; 2: CD005133.
79. Kliem V, Fricke L, Wollbrink T, Burg M, Radermacher J, Rohde F., Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: Results of a randomized clinical trial. Am J Transplant 2008; 8: 975-983.
80. Reischig T, Hribova P, Jindra P, et al., Long-term outcomes of pre-emptive valganciclovir compared with valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation. J Am Soc Nephrol 2012; 23: 1588-1597.
81. Emery VC., Human herpesviruses 6 and 7 in solid organ transplant recipients. Clin Infect Dis 2001; 32: 1357-1360.
82. Lautenschlager I, Razonable RR., Human herpesvirus-6 infections in kidney, liver, lung, and heart transplantation: Review. Transpl Int 2012; 25: 493-502.
83. Abdel Massih RC, Razonable RR,. Human herpesvirus 6 infections after liver transplantation. World J Gastroenterol 2009; 15: 2561-2569.
84. Ablashi DV, Devin CL, Yoshikawa T, et al., Review part 3: Human herpesvirus-6 in multiple non-neurological diseases. J Med Virol 2010; 82: 1903-1910.
85. Jacobs F, Knoop C, Brancart F, et al., Human herpesvirus-6 infection after lung and heart-lung transplantation: A prospective longitudinal study. Transplantation 2003; 75: 1996-2001.
86. Ljungman P, Singh N., Human herpesvirus-6 infection in solid organ and stem cell transplant recipients. J Clin Virol 2006; 37(Suppl 1): S87 -S91.
87. Kuhl U, Lassner D, Wallaschek N, et al., Chromosomally integrated human herpesvirus 6 in heart failure: Prevalence and treatment. Eur J Heart Fail 2015; 17: 9-19.
88. de Ona M, Melon S, Rodriguez JL, Sanmartin JC, Bernardo MJ., Association between human herpesvirus type 6 and type 7, and cytomegalovirus disease in heart transplant recipients. Transplant Proc 2002; 34: 75-76.
89. DesJardin JA, Cho E, Supran S, Gibbons L, Werner BG, Snydman DR,. Association of human herpesvirus 6 reactivation with severe cytomegalovirus-associated disease in orthotopic liver transplant recipients. Clin Infect Dis 2001; 33: 1358-1362.
90. DesJardin JA, Gibbons L, Cho E, et al., Human herpesvirus 6 reactivation is associated with cytomegalovirus infection and syndromes in kidney transplant recipients at risk for primary cytomegalovirus infection. J Infect Dis 1998; 178: 1783-1786.
91. Herbein G, Strasswimmer J, Altieri M, Woehl-Jaegle ML, Wolf P, Obert G., Longitudinal study of human herpesvirus 6 infection in organ transplant recipients. Clin Infect Dis 1996; 22: 171-173.
92. Lautenschlager I, Lappalainen M, Linnavuori K, Suni J, Hockerstedt K., CMV infection is usually associated with concurrent HHV-6 and HHV-7 antigenemia in liver transplant patients. J Clin Virol 2002; 25(Suppl 2): S57 -S61.
93. Lautenschlager I, Linnavuori K, Hockerstedt K., Human herpesvirus-6 antigenemia after liver transplantation. Transplantation 2000; 69: 2561-2566.
94. Lautenschlager I, Linnavuori K, Lappalainen M, Suni J, Hockerstedt K., HHV-6 reactivation is often associated with CMV infection in liver transplant patients. Transpl Int 2000; 13(Suppl 1): S351 -S353.
95. Lehto JT, Halme M, Tukiainen P, Harjula A, Sipponen J, Lautenschlager I., Human herpesvirus-6 and -7 after lung and heart-lung transplantation. J Heart Lung Transplant 2007; 26: 41-47.
96. Humar A, Kumar D, Caliendo AM, et al., Clinical impact of human herpesvirus 6 infection after liver transplantation. Transplantation 2002; 73: 599-604.
97. Dockrell DH, Prada J, Jones MF, et al., Seroconversion to human herpesvirus 6 following liver transplantation is a marker of cytomegalovirus disease. J Infect Dis 1997; 176: 1135-1140.
98. Ross DJ, Chan RC, Kubak B, Laks H, Nichols WS., Bronchiolitis obliterans with organizing pneumonia: Possible association with human herpesvirus-7 infection after lung transplantation. Transplant Proc 2001; 33: 2603-2606.
99. Fernandez-Ruiz M, Kumar D, Husain S, et al., Utility of a monitoring strategy for human herpesviruses 6 and 7 viremia after liver transplantation: A randomized clinical trial. Transplantation 2015; 99: 106-113.
100. Egli A, Infanti L, Dumoulin A, et al., Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis 2009; 199: 837-846.
101. Munoz P, Fogeda M, Bouza E, et al., Prevalence of BK virus replication among recipients of solid organ transplants. Clin Infect Dis 2005; 41: 1720-1725.
102. Dupont PJ, Manuel O, Pascual M., Infection and chronic allograft dysfunction. Kidney Int Suppl 2010 S47 -S53.
103. Hirsch HH, Steiger J., Polyomavirus BK. Lancet Infect Dis 2003; 3: 611-623.
104. Ramos E, Drachenberg CB, Wali R, Hirsch HH., The decade of polyomavirus BK-associated nephropathy: State of affairs. Transplantation 2009; 87: 621-630.
105. Fishman JA., BK virus nephropathy-polyomavirus adding insult to injury. N Engl J Med 2002; 347: 527-530.
106. Chen Y, Trofe J, Gordon J, Autissier P, Woodle ES, Koralnik IJ., BKV and JCV large T antigen-specific CD8+ T cell response in HLA A0201+ kidney transplant recipients with polyomavirus nephropathy and patients with progressive multifocal leukoencephalopathy. J Clin Virol 2008; 42: 198-202.
107. Hassig A, Roos M, Etter A, et al., Association of BK viremia with human leukocyte antigen mismatches and acute rejection, but not with type of calcineurin inhibitor. Transpl Infect Dis 2014; 16: 44-54.
108. Hirsch HH, Knowles W, Dickenmann M, et al., Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 2002; 347: 488-496.
109. Buehrig CK, Lager DJ, Stegall MD, et al., Influence of surveillance renal allograft biopsy on diagnosis and prognosis of polyomavirus-associated nephropathy. Kidney Int 2003; 64: 665-673.
110. Drachenberg CB, Papadimitriou JC, Hirsch HH, et al., Histological patterns of polyomavirus nephropathy: Correlation with graft outcome and viral load. Am J Transplant 2004; 4: 2082-2092.
111. Ramos E, Drachenberg CB, Papadimitriou JC, et al., Clinical course of polyoma virus nephropathy in 67 renal transplant patients. J Am Soc Nephrol 2002; 13: 2145-2151.
112. Dharnidharka VR, Cherikh WS, Abbott KC., An OPTN analysis of national registry data on treatment of BK virus allograft nephropathy in the United States. Transplantation 2009; 87: 1019-1026.
113. Barton TD, Blumberg EA, Doyle A, et al., A prospective cross-sectional study of BK virus infection in non-renal solid organ transplant recipients with chronic renal dysfunction. Transpl Infect Dis 2006; 8: 102-107.
114. Doucette KE, Pang XL, Jackson K, et al., Prospective monitoring of BK polyomavirus infection early posttransplantation in nonrenal solid organ transplant recipients. Transplantation 2008; 85: 1733-1736.
115. Schmid H, Burg M, Kretzler M, Banas B, Grone HJ, Kliem V., BK virus associated nephropathy in native kidneys of a heart allograft recipient. Am J Transplant 2005; 5: 1562-1568.
116. Schwarz A, Mengel M, Haller H, Niedermeyer J., Polyoma virus nephropathy in native kidneys after lung transplantation. Am J Transplant 2005; 5: 2582-2585.
117. Egli A, Helmersen DS, Taub K, Hirsch HH, Johnson A., Renal failure five years after lung transplantation due to polyomavirus BK-associated nephropathy. Am J Transplant 2010; 10: 2324-2330.
118. Loeches B, Valerio M, Palomo J, Bouza E, Munoz P., BK virus in heart transplant recipients: A prospective study. J Heart Lung Transplant 2011; 30: 109-111.
119. Loeches B, Valerio M, Perez M, et al., BK virus in liver transplant recipients: A prospective study. Transplant Proc 2009; 41: 1033-1037.
120. Thomas LD, Milstone AP, Vilchez RA, Zanwar P, Butel JS, Dummer JS., Polyomavirus infection and its impact on renal function and long-term outcomes after lung transplantation. Transplantation 2009; 88: 360-366.
121. Viswesh V, Yost SE, Kaplan B., The prevalence and implications of BK virus replication in non-renal solid organ transplant recipients: A systematic review. Transplant Rev (Orlando) 2015; 29: 175-180.
122. Lopez-Medrano F, Aguado JM, Lizasoain M, et al., Clinical implications of respiratory virus infections in solid organ transplant recipients: A prospective study. Transplantation 2007; 84: 851-856.
123. Manuel O, Estabrook M; AST Infectious Diseases Community of Practice. RNA respiratory viruses in solid organ transplantation. Am J Transplant 2013; 13(Suppl 4): 212-219.
124. Valentine VG, Gupta MR, Walker JE Jr, et al. Effect of etiology and timing of respiratory tract infections on development of bronchiolitis obliterans syndrome. J Heart Lung Transplant 2009; 28: 163-169.
125. Vilchez RA, McCurry K, Dauber J, et al., Influenza virus infection in adult solid organ transplant recipients. Am J Transplant 2002; 2: 287-291.
126. Cordero E, Perez-Romero P, Moreno A, et al., Pandemic influenza A(H1N1) virus infection in solid organ transplant recipients: Impact of viral and non-viral co-infection. Clin Microbiol Infect 2012; 18: 67-73.
127. Freitas TV, Ono G, Correa L, et al., Clinical manifestations and evolution of infection by influenza A (H1N1) in kidney transplant recipients. J Bras Nefrol 2011; 33: 136-141.
128. Ng BJ, Glanville AR, Snell G, et al., The impact of pandemic influenza A H1N1 2009 on Australian lung transplant recipients. Am J Transplant 2011; 11: 568-574.
129. Hopkins P, McNeil K, Kermeen F, et al., Human metapneumovirus in lung transplant recipients and comparison to respiratory syncytial virus. Am J Respir Crit Care Med 2008; 178: 876-881.
130. Raza K, Ismailjee SB, Crespo M, et al., Successful outcome of human metapneumovirus (hMPV) pneumonia in a lung transplant recipient treated with intravenous ribavirin. J Heart Lung Transplant 2007; 26: 862-864.
131. Kaiser L, Aubert JD, Pache JC, et al., Chronic rhinoviral infection in lung transplant recipients. Am J Respir Crit Care Med 2006; 174: 1392-1399.
132. Billings JL, Hertz MI, Savik K, Wendt CH., Respiratory viruses and chronic rejection in lung transplant recipients. J Heart Lung Transplant 2002; 21: 559-566.
133. Kumar D, Erdman D, Keshavjee S, et al., Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant. Am J Transplant 2005; 5: 2031-2036.
134. Husain S, Singh N., Bronchiolitis obliterans and lung transplantation: Evidence for an infectious etiology. Semin Respir Infect 2002; 17: 310-314.
135. Kumar D, Husain S, Chen MH, et al., A prospective molecular surveillance study evaluating the clinical impact of community-acquired respiratory viruses in lung transplant recipients. Transplantation 2010; 89: 1028-1033.
136. Vu DL, Bridevaux PO, Aubert JD, Soccal PM, Kaiser L., Respiratory viruses in lung transplant recipients: A critical review and pooled analysis of clinical studies. Am J Transplant 2011; 11: 1071-1078.
137. Soccal PM, Aubert JD, Bridevaux PO, et al., Upper and lower respiratory tract viral infections and acute graft rejection in lung transplant recipients. Clin Infect Dis 2010; 51: 163-170.
138. Weigt SS, Copeland CA, Derhovanessian A, et al., Colonization with small conidia Aspergillus species is associated with bronchiolitis obliterans syndrome: A two-center validation study. Am J Transplant 2013; 13: 919-927.
139. Sayah DM, Koff JL, Leard LE, Hays SR, Golden JA, Singer JP., Rhinovirus and other respiratory viruses exert different effects on lung allograft function that are not mediated through acute rejection. Clin Transplant 2013; 27: E64 -E71.
140. Bridevaux PO, Aubert JD, Soccal PM, et al., Incidence and outcomes of respiratory viral infections in lung transplant recipients: A prospective study. Thorax 2014; 69: 32-38.
141. Cordero E, Aydillo T, Farinas MC, et al., Immunosuppressed patients with pandemic influenza A 2009 (H1N1) virus infection. Eur J Clin Microbiol Infect Dis 2012; 31: 547-556.
142. Hurst FP, Lee JJ, Jindal RM, Agodoa LY, Abbott KC., Outcomes associated with influenza vaccination in the first year after kidney transplantation. Clin J Am Soc Nephrol 2011; 6: 1192-1197.
143. Perez-Romero P, Aydillo TA, Perez-Ordonez A, et al., Reduced incidence of pneumonia in influenza-vaccinated solid organ transplant recipients with influenza disease. Clin Microbiol Infect 2012; 18: E533 -E540.
144. Wong RJ, Aguilar M, Cheung R, et al., Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 2015; 148: 547-555.
145. Gane EJ, Portmann BC, Naoumov NV, et al., Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334: 815-820.
146. Chinnadurai R, Velazquez V, Grakoui A., Hepatic transplant and HCV: A new playground for an old virus. Am J Transplant 2012; 12: 298-305.
147. Biggins SW, Gralla J, Dodge JL, et al., Survival benefit of repeat liver transplantation in the United States: A serial MELD analysis by hepatitis C status and donor risk index. Am J Transplant 2014; 14: 2588-2594.
148. Razonable RR, Burak KW, van Cruijsen H, et al., The pathogenesis of hepatitis C virus is influenced by cytomegalovirus. Clin Infect Dis 2002; 35: 974-981.
149. Rosen HR, Chou S, Corless CL, et al., Cytomegalovirus viremia: Risk factor for allograft cirrhosis after liver transplantation for hepatitis C. Transplantation 1997; 64: 721-726.
150. Singh N, Husain S, Carrigan DR, et al., Impact of human herpesvirus-6 on the frequency and severity of recurrent hepatitis C virus hepatitis in liver transplant recipients. Clin Transplant 2002; 16: 92-96.
151. Humar A, Kumar D, Raboud J, et al., Interactions between cytomegalovirus, human herpesvirus-6, and the recurrence of hepatitis C after liver transplantation. Am J Transplant 2002; 2: 461-466.
152. Baid-Agrawal S, Pascual M, Moradpour D, Somasundaram R, Muche M., Hepatitis C virus infection and kidney transplantation in 2014: What's new ? Am J Transplant 2014; 14: 2206-2220.
153. Baid S, Cosimi AB, Tolkoff-Rubin N, Colvin RB, Williams WW, Pascual M., Renal disease associated with hepatitis C infection after kidney and liver transplantation. Transplantation 2000; 70: 255-261.
154. Morales JM, Dominguez-Gil B, Sanz-Guajardo D, Fernandez J, Escuin F., The influence of hepatitis B and hepatitis C virus infection in the recipient on late renal allograft failure. Nephrol Dial Transplant 2004; 19 (Suppl 3): iii72-iii76.
155. Forman JP, Tolkoff-Rubin N, Pascual M, Lin J., Hepatitis C, acute humoral rejection, and renal allograft survival. J Am Soc Nephrol 2004; 15: 3249-3255.
156. Lopez-Medrano F, Fernandez-Ruiz M, Morales JM, et al., Impact of hepatitis C virus infection on the risk of infectious complications after kidney transplantation: Data from the RESITRA/REIPI cohort. Transplantation 2011; 92: 543-549.
157. Carbone M, Mutimer D, Neuberger J., Hepatitis C virus and nonliver solid organ transplantation. Transplantation 2013; 95: 779-786.
158. Fong TL, Hou L, Hutchinson IV, Cicciarelli JC, Cho YW., Impact of hepatitis C infection on outcomes after heart transplantation. Transplantation 2009; 88: 1137-1141.
159. Kamar N, Izopet J, Alric L, Guilbeaud-Frugier C, Rostaing L., Hepatitis C virus-related kidney disease: An overview. Clin Nephrol 2008; 69: 149-160.
160. Bunchorntavakul C, Maneerattanaporn M, Chavalitdhamrong D., Management of patients with hepatitis C infection and renal disease. World J Hepatol 2015; 7: 213-225.
161. Forns X, Charlton M, Denning J, et al., Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C following liver transplantation. Hepatology 2015; 61: 1485-1494.
162. Gane EJ, Agarwal K., Directly acting antivirals (DAAs) for the treatment of chronic hepatitis C virus infection in liver transplant patients: "A flood of opportunity." Am J Transplant 2014; 14: 994-1002.
163. Mueller N, Saccilotto R, Meylan P, et al., Opportunistic infections after solid organ transplantation (SOT) are rare in the Swiss Transplant Cohort Study (STCS). Transplantation 2014; 98: 165.
164. Aguilar-Guisado M, Givalda J, Ussetti P, et al., Pneumonia after lung transplantation in the RESITRA cohort: A multicenter prospective study. Am J Transplant 2007; 7: 1989-1996.
165. Vos R, Vanaudenaerde BM, Geudens N, Dupont LJ, Van Raemdonck DE, Verleden GM., Pseudomonal airway colonisation: Risk factor for bronchiolitis obliterans syndrome after lung transplantation ? Eur Respir J 2008; 31: 1037-1045.
166. Borthwick LA, Corris PA, Mahida R, et al., TNFalpha from classically activated macrophages accentuates epithelial to mesenchymal transition in obliterative bronchiolitis. Am J Transplant 2013; 13: 621-633.
167. Manuel O, Lien D, Weinkauf J, Humar A, Cobos I, Kumar D., Methicillin-resistant Staphylococcus aureus infection after lung transplantation: 5-Year review of clinical and molecular epidemiology. J Heart Lung Transplant 2009; 28: 1231-1236.
168. Shields RK, Clancy CJ, Minces LR, et al., Staphylococcus aureus infections in the early period after lung transplantation: Epidemiology, risk factors, and outcomes. J Heart Lung Transplant 2012; 31: 1199-1206.
169. Gregson AL, Wang X, Injean P, et al., Staphylococcus via an interaction with the ELR+ CXC chemokine ENA-78 is associated with BOS. Am J Transplant 2015; 15: 792-799.
170. Ariza-Heredia EJ, Beam EN, Lesnick TG, Cosio FG, Kremers WK, Razonable RR., Impact of urinary tract infection on allograft function after kidney transplantation. Clin Transplant 2014; 28: 683-690.
171. Vidal E, Torre-Cisneros J, Blanes M, et al., Bacterial urinary tract infection after solid organ transplantation in the RESITRA cohort. Transpl Infect Dis 2012; 14: 595-603.
172. Almond PS, Matas A, Gillingham K, et al., Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993; 55: 752-756; discussion 756-757.
173. Kamath NS, John GT, Neelakantan N, Kirubakaran MG, Jacob CK., Acute graft pyelonephritis following renal transplantation. Transpl Infect Dis 2006; 8: 140-147.
174. Rice JC, Peng T, Kuo YF, et al., Renal allograft injury is associated with urinary tract infection caused by Escherichia coli bearing adherence factors. Am J Transplant 2006; 6: 2375-2383.
175. Abbott KC, Swanson SJ, Richter ER, et al., Late urinary tract infection after renal transplantation in the United States. Am J Kidney Dis 2004; 44: 353-362.
176. Dupont PJ, Psimenou E, Lord R, Buscombe JR, Hilson AJ, Sweny P., Late recurrent urinary tract infections may produce renal allograft scarring even in the absence of symptoms or vesicoureteric reflux. Transplantation 2007; 84: 351-355.
177. Lee JR, Bang H, Dadhania D, et al., Independent risk factors for urinary tract infection and for subsequent bacteremia or acute cellular rejection: A single-center report of 1166 kidney allograft recipients. Transplantation 2013; 96: 732-738.
178. Al-Hasan MN, Razonable RR, Kremers WK, Baddour LM., Impact of Gram-negative bloodstream infection on long-term allograft survival after kidney transplantation. Transplantation 2011; 91: 1206-1210.
179. Pelle G, Vimont S, Levy PP, et al., Acute pyelonephritis represents a risk factor impairing long-term kidney graft function. Am J Transplant 2007; 7: 899-907.
180. Fiorante S, Lopez-Medrano F, Lizasoain M, et al., Systematic screening and treatment of asymptomatic bacteriuria in renal transplant recipients. Kidney Int 2010; 78: 774-781.
181. Bodro M, Sanclemente G, Lipperheide I, et al., Impact of antibiotic resistance on the development of recurrent and relapsing symptomatic urinary tract infection in kidney recipients. Am J Transplant 2015; 15: 1021-1027.
182. Gupta S., Chronic infection in the aetiology of atherosclerosis-focus on Chlamydia pneumoniae. Atherosclerosis 1999; 143: 1-6.
183. Wong YK, Gallagher PJ, Ward ME., Chlamydia pneumoniae and atherosclerosis. Heart 1999; 81: 232-238.
184. Campbell LA, Rosenfeld ME., Persistent C., pneumoniae infection in atherosclerotic lesions: Rethinking the clinical trials. Front Cell Infect Microbiol 2014; 4: 34.
185. Grayston JT. Antibiotic treatment of atherosclerotic cardiovascular disease. Circulation 2003; 107: 1228-1230.
186. Subramanian AK, Quinn TC, Kickler TS, Kasper EK, Tucker PC., Correlation of chlamydia pneumoniae infection and severity of accelerated graft arteriosclerosis after cardiac transplantation. Transplantation 2002; 73: 761-764.
187. Wittwer T, Pethig K, Heublein B, et al., Impact of chronic infection with chlamydia pneumoniae on incidence of cardiac allograft vasculopathy. Transplantation 2000; 69: 1962-1964.
188. Rosenfeld ME, Campbell LA., Pathogens and atherosclerosis: Update on the potential contribution of multiple infectious organisms to the pathogenesis of atherosclerosis. Thromb Haemost 2011; 106: 858-867.
189. Danesh J., Antibiotics in the prevention of heart attacks. Lancet 2005; 365: 365-367.
190. Husain S, Kahane S, Friedman MG, et al., Simkania negevensis in bronchoalveolar lavage of lung transplant recipients: A possible association with acute rejection. Transplantation 2007; 83: 138-143.
191. Kotsimbos TC, Snell GI, Levvey B, et al., Chlamydia pneumoniae serology in donors and recipients and the risk of bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2005; 79: 269-275.
192. Glanville AR, Gencay M, Tamm M, et al., Chlamydia pneumoniae infection after lung transplantation. J Heart Lung Transplant 2005; 24: 131-136.
193. Tissot F, Pascual M, Hullin R, et al., Impact of targeted antifungal prophylaxis in heart transplant recipients at high risk for early invasive fungal infection. Transplantation 2014; 97: 1192-1197.
194. Weigt SS, Elashoff RM, Huang C, et al., Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome. Am J Transplant 2009; 9: 1903-1911.
195. Husain S, Paterson DL, Studer S, et al., Voriconazole prophylaxis in lung transplant recipients. Am J Transplant 2006; 6: 3008-3016.
196. Monforte V, Roman A, Gavalda J, et al., Nebulized amphotericin B concentration and distribution in the respiratory tract of lung-transplanted patients. Transplantation 2003; 75: 1571-1574.
197. Fortun J, Martin-Davila P, Moreno S, et al., Risk factors for invasive aspergillosis in liver transplant recipients. Liver Transpl 2002; 8: 1065-1070.
198. Husni RN, Gordon SM, Longworth DL, et al., Cytomegalovirus infection is a risk factor for invasive aspergillosis in lung transplant recipients. Clin Infect Dis 1998; 26: 753-755.
199. Singh N, Suarez JF, Avery R, et al., Risk factors and outcomes in lung transplant recipients with nodular invasive pulmonary aspergillosis. J Infect 2013; 67: 72-78.
200. Manuel O, Husain S, Kumar D, et al., Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: A multicenter cohort study. Clin Infect Dis 2013; 56: 817-824.
201. Maluf DG, Dumur CI, Suh JL, et al., The urine microRNA profile may help monitor post-transplant renal graft function. Kidney Int 2014; 85: 439-449.
202. Pham MX, Teuteberg JJ, Kfoury AG, et al., Gene-expression profiling for rejection surveillance after cardiac transplantation. N Engl J Med 2010; 362: 1890-1900.
203. Griffiths PD, Stanton A, McCarrell E, et al., Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: A phase 2 randomised placebo-controlled trial. Lancet 2011; 377: 1256-1263.
204. Billips BK, Yaggie RE, Cashy JP, Schaeffer AJ, Klumpp DJ., A live-attenuated vaccine for the treatment of urinary tract infection by uropathogenic Escherichia coli. J Infect Dis 2009; 200: 263-272.
205. Gane E, Saliba F, Valdecasas GJ, et al., Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected] [erratum in Lancet 1998; 351: 454]. Lancet 1997; 350: 1729-1733.
206. Valantine HA, Gao SZ, Menon SG, et al., Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: A post hoc analysis of a randomized, placebo-controlled study. Circulation 1999; 100: 61-66.
207. Witzke O, Hauser IA, Bartels M, et al., Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-Year results of a randomized clinical trial. Transplantation 2012; 93: 61-68.
208. Humar A, Lebranchu Y, Vincenti F, et al., The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010; 10: 1228-1237.
209. Palmer SM, Limaye AP, Banks M, et al., Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: A randomized, controlled trial. Ann Intern Med 2010; 152: 761-769.
210. Fiorante S, Fernandez-Ruiz M, Lopez-Medrano F, et al. Acute graft pyelonephritis in renal transplant recipients: Incidence, risk factors and long-term outcome. Nephrol Dial Transplant 2011; 26: 1065-1073.